Clinical Trial Update: Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating sintilimab plus pemigatinib in PD-L1–positive and FGFR-mutated advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pemigatinib (pemigatinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Conditions: Advanced Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN